Last updated: September 8, 2026
ACT-541468 is daridorexant, a dual orexin receptor antagonist developed by Actelion and later commercialized by Idorsia under the brand Quviviq. The drug is approved in the United States and European Union for insomnia characterized by difficulties with sleep onset or sleep maintenance. Its commercial opportunity is meaningful but constrained by controlled-substance requirements, competition from generic sedative-hypnotics and other orexin antagonists, and slow prescriber adoption.
The base-case outlook is for Quviviq to remain a commercially viable branded insomnia product through the second half of the 2020s, with global annual sales likely in the low hundreds of millions of dollars rather than reaching blockbuster scale. The key value drivers are U.S. prescription growth, expansion into primary-care prescribing, payer coverage, and the timing of generic entry after regulatory and patent barriers expire.
What is ACT-541468 and how does daridorexant work?
ACT-541468 is the development code for daridorexant, an orally administered dual orexin receptor antagonist. It blocks orexin OX1 and OX2 receptors, reducing wake signaling in the central nervous system.
Daridorexant is differentiated from benzodiazepines and Z-drugs because it targets the orexin system rather than broadly enhancing gamma-aminobutyric acid signaling. The FDA-approved strengths are 25 mg and 50 mg, taken once nightly within 30 minutes before bedtime, with at least seven hours remaining before planned awakening (FDA, 2022).
Development history
| Milestone |
Date |
Detail |
| Actelion begins clinical development |
2010s |
Program developed as a selective dual orexin receptor antagonist |
| Phase 3 registration studies |
2018-2020 |
Studies 303 and 304 evaluated sleep onset, sleep maintenance and daytime functioning |
| Actelion acquired by Johnson & Johnson |
2017 |
Actelion assets transferred into Janssen |
| Idorsia established |
2017 |
Actelion research and development operations transferred to Idorsia |
| U.S. FDA approval |
January 7, 2022 |
Quviviq approved under NDA 214985 |
| U.S. controlled-substance scheduling |
May 2022 |
Daridorexant classified as Schedule IV |
| European authorization |
November 2022 |
Quviviq authorized in the European Union |
| U.S. commercial launch |
2022 |
Idorsia began commercial distribution in the United States |
The pivotal studies showed statistically significant improvements in objective and subjective sleep measures, with the 50 mg dose producing the strongest efficacy signal. The product label also includes warnings concerning next-day impairment, worsening depression or suicidal ideation, complex sleep behaviors, sleep paralysis, hallucinations and abuse potential (FDA, 2022).
What is the current regulatory status of Quviviq?
Quviviq is FDA-approved for adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. The product is not approved for pediatric use and is not indicated for treatment of narcolepsy.
The FDA approval was based on two randomized Phase 3 studies:
- Study 303 evaluated 25 mg and 50 mg doses over three months.
- Study 304 evaluated 10 mg, 25 mg and 50 mg doses over three months.
- A 40-week extension study assessed longer-term exposure.
The 50 mg dose produced the most consistent improvement in latency to persistent sleep, wake after sleep onset and subjective total sleep time. The label states that daridorexant has not been adequately studied in patients with severe obstructive sleep apnea or severe chronic obstructive pulmonary disease.
Daridorexant is a Schedule IV controlled substance in the United States. This status creates prescribing and distribution obligations, but it is less restrictive than Schedule II and Schedule III products. The controlled-substance classification can still slow primary-care adoption and increase pharmacy-level friction.
How does daridorexant compare with other orexin antagonists?
Daridorexant competes in the dual orexin receptor antagonist, or DORA, class. The principal U.S. comparators are suvorexant and lemborexant.
| Product |
Active ingredient |
U.S. brand |
Sponsor |
Initial U.S. approval |
Key commercial issue |
| Quviviq |
Daridorexant |
Quviviq |
Idorsia |
2022 |
Later entrant, newer patent estate |
| Belsomra |
Suvorexant |
Belsomra |
Merck |
2014 |
Established prescriber base and managed-care presence |
| Dayvigo |
Lemborexant |
Dayvigo |
Eisai |
2019 |
Earlier market entry and broader commercial history |
| Orexin generic products |
Various |
Not yet broadly available |
Generic manufacturers |
Not established |
Patent and ANDA timing remain decisive |
Daridorexant has a commercially relevant differentiation claim around next-day functioning. In clinical studies, the 50 mg dose improved self-reported daytime sleepiness and daytime functioning relative to placebo. That positioning is useful against older hypnotics, but it has not eliminated the cost advantage of generic zolpidem, eszopiclone and temazepam.
The DORA category remains smaller than the overall prescription insomnia market. Prescribers often reserve newer agents for patients who fail or cannot tolerate generic therapies.
What patents protect daridorexant and when does Quviviq lose exclusivity?
The principal intellectual-property protection for daridorexant is based on composition-of-matter and pharmaceutical-use patent families. Additional protection may cover formulations, dosage strengths, treatment methods and pharmaceutical compositions.
The U.S. Orange Book should be treated as the controlling source for currently listed patents and use codes. Public patent records identify daridorexant-related U.S. patent protection extending into the 2030s. The effective generic-entry date will depend on:
- The latest valid Orange Book-listed patent.
- Any patent-term adjustment or pediatric extension.
- Whether an ANDA applicant files a Paragraph IV certification.
- The timing and outcome of patent litigation.
- Any settlement restricting the generic launch date.
Orange Book and Paragraph IV risk
Quviviq is an NDA product and is subject to Orange Book listing. A generic applicant would generally need to file an ANDA with certifications addressing listed patents. A Paragraph IV certification would assert that a listed patent is invalid, unenforceable or not infringed.
A Paragraph IV filing can trigger a 30-month stay of FDA approval if the NDA holder files suit within the statutory period. The stay does not necessarily prevent a court from allowing earlier launch if the patent claims are defeated or found not infringed.
No biosimilar pathway applies to daridorexant. It is a small molecule, so the relevant competitive threat is an ANDA-based generic, not a biosimilar.
Formulation and method-of-use protection
Formulation patents could cover tablets, excipients, particle characteristics, dissolution profiles or dosage combinations. Method-of-use patents could cover treatment of insomnia, dosing regimens, patient populations or improvements in daytime functioning.
These secondary patents are generally less robust than a valid composition-of-matter patent. Their commercial value depends on claim scope, Orange Book listing, infringement evidence and the ability to obtain an injunction or settlement that delays generic launch.
What patent litigation affects Quviviq?
Publicly disclosed litigation risk for Quviviq has been lower than for many large oncology, immunology and specialty-pharmacy products because the product has generated a smaller revenue base and has not yet reached the most aggressive stage of generic competition.
The main litigation risk is prospective rather than an established market-disrupting dispute:
- ANDA applicants may challenge compound or use patents.
- Idorsia may file patent litigation after receiving a Paragraph IV notice.
- Generic applicants may pursue at-risk launch after an adverse preliminary ruling.
- Patent settlements may establish a negotiated entry date before final patent expiration.
The financial exposure from litigation is meaningful because a generic DORA could rapidly reduce net price and market share. The exposure is lower than for a billion-dollar product because current Quviviq sales are materially below blockbuster levels.
How strong is the daridorexant patent estate?
The estate has moderate-to-strong commercial value while core compound protection remains enforceable. Its strength is based on the following factors:
- Daridorexant is a chemically defined small molecule with potential composition-of-matter protection.
- The product has multiple approved strengths.
- The product has differentiated clinical claims around sleep maintenance and daytime functioning.
- Formulation and method-of-use patents can create additional litigation positions.
- The market is sufficiently concentrated that a successful patent challenge could materially affect pricing.
The estate has limitations:
- Small-molecule patents are vulnerable to validity and obviousness challenges.
- Generic applicants can design around narrow formulation claims.
- The DORA class has multiple branded competitors.
- Generic insomnia medicines impose substantial price pressure even before direct daridorexant generics enter.
- The Schedule IV classification may limit rapid volume expansion.
Overall, the patent estate supports continued branded sales into the 2030s if core claims survive challenges. The commercial protection period is likely shorter than the nominal patent term because payers can force discounts and physicians can substitute cheaper alternatives before legal generic entry.
What are Quviviq sales and revenue projections?
Idorsia reported Quviviq sales of approximately CHF 55 million in 2023, compared with approximately CHF 21 million in 2022. The figures reflect a product still in the early adoption phase and include market expansion across the United States and Europe (Idorsia Pharmaceuticals Ltd., 2024).
Base-case projection
| Year |
Estimated global net sales |
Market interpretation |
| 2023 |
CHF 55 million reported |
Early launch and formulary development |
| 2024 |
CHF 70-90 million |
U.S. prescription growth and European expansion |
| 2025 |
CHF 100-140 million |
Increased awareness and broader payer access |
| 2026 |
CHF 140-190 million |
Peak adoption period in the base case |
| 2027 |
CHF 160-220 million |
Mature branded growth before major generic pressure |
| 2028 onward |
Variable |
Dependent on patent challenges and negotiated generic entry |
These figures are scenario estimates, not company guidance. The base case assumes continued prescription growth, no major safety signal and gradual payer expansion.
Upside scenario
An upside case could produce annual sales above CHF 250 million if:
- Quviviq becomes a preferred branded DORA.
- Primary-care prescribing expands materially.
- The product gains stronger positioning for patients concerned about next-day impairment.
- U.S. commercial coverage improves.
- Generic entry is delayed by successful patent litigation or settlement.
Downside scenario
A downside case would place annual sales below CHF 100 million if:
- Payers maintain strict prior authorization.
- Prescribers continue to favor generic zolpidem and eszopiclone.
- Dayvigo and Belsomra retain stronger formulary positions.
- A successful Paragraph IV challenge accelerates generic competition.
- Controlled-substance requirements limit refill continuity and prescribing volume.
What are the main commercial risks for daridorexant?
The leading commercial risks are pricing, competition and adoption rather than clinical failure.
Payer and reimbursement pressure
Insomnia therapy is a large but price-sensitive market. Generic treatments are inexpensive and widely available. Quviviq must demonstrate clinical and functional benefits that justify a branded price.
Competitive DORA products
Belsomra and Dayvigo have longer market histories. Physicians familiar with those products may not switch patients unless Quviviq offers better formulary access or a clear tolerability advantage.
Safety and abuse potential
Daridorexant has lower broad CNS depressant activity than benzodiazepines but remains a controlled substance. Label warnings concerning impairment and complex sleep behaviors can limit prescribing in older adults and patients using other CNS depressants.
Manufacturing and supply
Daridorexant is a conventional small-molecule tablet. Manufacturing is less technically difficult than biologic production, and biosimilar-style manufacturing barriers do not apply. The main barriers are chemical process know-how, regulatory approval, quality control and patent clearance.
Geographic coverage
The United States is the principal value market. European commercialization is fragmented across national reimbursement systems, and pricing varies by country. Approval does not guarantee rapid commercial uptake in Europe because health technology assessment and reimbursement negotiations can delay broad access.
How does Quviviq compare with Dayvigo and Belsomra?
Quviviq is the newest of the three major branded DORAs in the United States. Dayvigo has an earlier launch and Belsomra has the longest commercial history. Quviviq's advantage is a newer clinical and patent profile. Its disadvantage is limited brand maturity and the need to displace both older DORAs and inexpensive generic hypnotics.
| Factor |
Quviviq |
Dayvigo |
Belsomra |
| Mechanism |
Dual OX1/OX2 antagonist |
Dual OX1/OX2 antagonist |
Dual OX1/OX2 antagonist |
| U.S. launch |
2022 |
2019 |
2014 |
| Main differentiation |
Sleep maintenance and daytime functioning |
Sleep onset and maintenance |
Established DORA brand |
| Generic competition |
Generic daridorexant not established |
Generic lemborexant not established |
Earlier generic risk profile |
| Commercial position |
Growth-stage brand |
Established challenger |
Mature incumbent |
Key Takeaways
- ACT-541468 is daridorexant, marketed as Quviviq.
- The drug is FDA-approved and authorized in the European Union for adult insomnia.
- The product is a Schedule IV dual orexin receptor antagonist.
- The most important competitive threats are generic hypnotics, Dayvigo and Belsomra.
- No biosimilar risk applies because daridorexant is a small molecule.
- U.S. patent protection extends into the 2030s based on publicly disclosed patent families, although actual generic-entry timing will depend on Orange Book listings and Paragraph IV litigation.
- Quviviq sales were approximately CHF 55 million in 2023.
- A reasonable base-case peak-sales range is approximately CHF 160 million to CHF 220 million annually.
- A larger outcome would require stronger U.S. payer coverage and primary-care adoption.
- Generic entry or a weak payer position could cap sales below CHF 100 million annually.
FAQs About ACT-541468 and Quviviq
Is ACT-541468 the same drug as Quviviq?
Yes. ACT-541468 is the development code for daridorexant, which is marketed as Quviviq.
Is daridorexant a benzodiazepine?
No. Daridorexant is a dual orexin receptor antagonist. It does not act through the benzodiazepine binding site or primarily through GABA-A receptor potentiation.
Is Quviviq approved for long-term insomnia treatment?
The FDA label supports treatment of adult insomnia, and clinical studies included a longer-term extension. Continued treatment should be based on clinical response, tolerability and reassessment of the underlying sleep disorder.
Can generic manufacturers make daridorexant?
They can seek approval through the ANDA pathway, subject to patent certifications, regulatory requirements and any resulting patent litigation. A generic launch date cannot be determined solely from FDA approval status.
Who owns the commercial rights to daridorexant?
Idorsia developed and commercializes daridorexant. Actelion originated the program before its corporate and asset transfers. Commercial rights can vary by territory and may be affected by distribution, licensing or co-commercialization arrangements.
References
-
U.S. Food and Drug Administration. (2022). Quviviq (daridorexant) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2022, January 7). FDA approves new drug for insomnia. FDA.
-
ClinicalTrials.gov. (2020). Study of daridorexant in patients with insomnia disorder: NCT03545191 and NCT03575132. U.S. National Library of Medicine.
-
Idorsia Pharmaceuticals Ltd. (2024). Annual report 2023. Idorsia Pharmaceuticals.
-
European Medicines Agency. (2022). Quviviq: EPAR product information. EMA.
-
U.S. Patent and Trademark Office. (2024). Patent and patent application records for daridorexant and orexin receptor antagonists. USPTO.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
